Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
10:56am, Tuesday, 04'th Nov 2025
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript
02:06am, Tuesday, 04'th Nov 2025
Xenon Pharmaceuticals Inc. ( XENE ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Colleen Alabiso Ian Mortimer - President, CEO, Principal Accounting Officer & Director Chris
Xenon Reports Third Quarter 2025 Financial Results & Business Update
04:01pm, Monday, 03'rd Nov 2025
– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to re
Xenon to Report Q3 2025 Financial Results on November 3, 2025
08:30am, Monday, 27'th Oct 2025
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
08:30am, Thursday, 16'th Oct 2025
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience Mr. Kelly is a proven strategic CFO with significant financial, operational and
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 07'th Oct 2025
VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini
Xenon Pharmaceuticals Inc. - Special Call
03:45pm, Monday, 06'th Oct 2025
Xenon Pharmaceuticals Inc. - Special Call Company Participants Ian Mortimer - Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Officer & Director James Empfield - Executi
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
04:01pm, Thursday, 25'th Sep 2025
VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clin
Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?
12:30pm, Wednesday, 10'th Sep 2025
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 29'th Aug 2025
VANCOUVER, British Columbia and BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clin
Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release
02:48pm, Tuesday, 12'th Aug 2025
Xenon Pharmaceuticals is advancing azetukalner in multiple phase 3 trials for focal onset seizures, with topline X-TOLE2 data expected in early 2026. Azetukalner's mechanism and prior dose-dependent e
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
11:21am, Tuesday, 12'th Aug 2025
XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.
Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript
11:44pm, Monday, 11'th Aug 2025
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Christopher John Kenney - Ch
Xenon Reports Second Quarter 2025 Financial Results & Business Update
04:01pm, Monday, 11'th Aug 2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-
Xenon to Report Q2 2025 Financial Results on August 11, 2025
08:01am, Monday, 04'th Aug 2025
VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developi
